文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

重症监护室军团菌肺炎的人口学特征与结局:一项回顾性多中心队列研究

Demographics and outcome of Legionella pneumonia in the intensive care unit: a retrospective multicenter cohort study.
PubMed 文献 · Crit Care · 2025-08-20
一句话结论军团菌肺炎需ECMO支持者28天死亡率与不需ECMO者无显著差异(25% vs 21%),尽管SOFA评分更高。

该回顾性多中心队列研究分析了2013至2023年瑞士苏黎世及德国汉诺威、波恩三所三级大学医院ICU收治的110例军团菌肺炎患者,中位年龄60岁,75%为男性,40%接受ECMO支持。ECMO组与非ECMO组28天死亡率无显著差异(25% vs 21%,OR 1.24,95%CI 0.49-3.05,p=0.64),尽管ECMO组入ICU 24小时后SOFA评分更高(12 vs 9,p<0.001)。仅57%患者在入ICU时接受了充分的军团菌抗生素覆盖,且与结局无差异。多变量分析显示医院获得性军团菌肺炎(OR 28.4,95%CI 3.44-614,p=0.006)和乳酸(OR 1.31,95%CI 1.05-1.75,p=0.031)是28天死亡的独立危险因素。作者认为,军团菌肺炎所致呼吸衰竭需ECMO者的死亡率低于已发表的总体ARDS人群数据,这一间接提示可能有助于临床医生决定是否启动或暂缓ECMO。

要点

  • 军团菌肺炎需ECMO支持者28天死亡率25%,不需ECMO者21%,两组无显著差异(OR 1.24,95%CI 0.49-3.05,p=0.64)。
  • ECMO组入ICU 24小时后SOFA评分显著更高(12 vs 9,p<0.001),但死亡率未相应升高。
  • 仅57%患者在入ICU时接受了充分的军团菌抗生素覆盖,充分与否与结局无差异。
  • 医院获得性军团菌肺炎(OR 28.4,95%CI 3.44-614,p=0.006)和乳酸(OR 1.31,95%CI 1.05-1.75,p=0.031)是28天死亡的独立危险因素。
  • 作者认为,军团菌肺炎所致呼吸衰竭需ECMO者的死亡率低于已发表的总体ARDS人群数据,这一间接提示可能支持临床医生决定是否启动或暂缓ECMO。

适用人群与场景

  • 2013至2023年瑞士苏黎世、德国汉诺威和波恩三所三级大学医院ICU收治的军团菌肺炎患者,共110例,中位年龄60岁,75%为男性。

处置流程与药物剂量

  • 40%的患者启动了ECMO支持。
  • 仅57%的患者在入ICU时接受了充分的军团菌抗生素覆盖。

研究设计与关键结果

  • 研究类型为回顾性多中心队列研究,纳入三所三级大学医院ICU的110例军团菌肺炎患者,中位年龄60岁,75%为男性。
  • ECMO支持在40%的患者中启动。
  • 总体28天死亡率ECMO组25% vs 非ECMO组21%,无显著差异(OR 1.24,95%CI 0.49-3.05,p=0.64)。
  • ECMO组入ICU 24小时后SOFA评分显著高于非ECMO组(12 vs 9,p<0.001)。
  • 仅57%的患者在入ICU时接受了充分的军团菌抗生素覆盖,充分与否与结局无差异。
  • 多变量分析显示医院获得性军团菌肺炎(OR 28.4,95%CI 3.44-614,p=0.006)和乳酸(OR 1.31,95%CI 1.05-1.75,p=0.031)是28天死亡的独立危险因素。

证据类型、等级与局限

  • 证据类型:回顾性多中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于军团菌肺炎所致ARDS需ECMO支持者,尽管SOFA评分更高,28天死亡率与不需ECMO者无显著差异(25% vs 21%)。
  • 作者认为,军团菌肺炎所致呼吸衰竭需ECMO者的死亡率低于已发表的总体ARDS人群数据,这一间接提示可能支持临床医生决定是否启动或暂缓ECMO。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Legionella pneumonia (LP) is a major cause of severe community-acquired pneumonia (CAP) that can lead to acute respiratory distress syndrome (ARDS) with high morbidity and mortality. ARDS may necessitate extracorporeal membrane oxygenation (ECMO) support, and evidence is limited about benefits of ECMO in LP. Therefore, we sought to analyze the clinical course, outcomes and predictive factors of ECMO patients with ARDS due to LP compared to non ECMO patients.

METHODS: This retrospective, multicenter cohort study analyzed ICU patients with LP across three tertiary university hospitals (Zurich, Switzerland; Hannover & Bonn, Germany) from 2013 to 2023. We examined demographics, clinical characteristics, and outcomes, with a focus on ECMO utilization and its impact on mortality.

RESULTS: A total of 110 patients were included, with a median age of 60 years and 75% male. ECMO support was initiated in 40%. The overall 28-day mortality did not differ between groups, with 21% without ECMO vs. 25% with ECMO (OR 1.24 (0.49-3.05, p = 0.64), despite higher degree of organ failure in the ECMO group (SOFA score 24 h after ICU admission 9 vs. 12, p < 0.001). Only 57% of patients had adequate antibiotic LP coverage at ICU admission with no differences in outcome. Multivariable analysis found hospital acquired LP (OR 28.4 (3.44-614), p = 0.006) and lactate (OR 1.31 (1.05-1.75), p = 0.031) as independent risk factor for 28-day mortality.

CONCLUSIONS: Patients suffering from LP requiring ECMO support had similar mortality rates compared to LP patients without ECMO support, despite higher SOFA scores. In addition, LP-induced respiratory failure requiring ECMO had a lower mortality rate compared to the published literature on the overall ARDS population. This indirect indication of a potential survival benefit may support bedside clinicians in their decision-making regarding ECMO initiation or withholding.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Hauffe T, Nalbant B, Wild L, et al. Demographics and outcome of Legionella pneumonia in the intensive care unit: a retrospective multicenter cohort study. Crit Care. 2025. PMID: 40835943. doi:10.1186/s13054-025-05524-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。